Philip H. Frost, M.D.

 

Dr. Philip Frost is a clinical professor of medicine at the University of California, San Francisco [UCSF] in the Department of Medicine and Cardiovascular

Research Institute. He is a clinician, clinical investigator, who for more than 40 years has worked in the field of cardiovascular risk reduction. His book entitled “Little Book for Heart and Blood Vessel Health” is an effort to translate clinical experience accrued in a university lipid clinic to the learned lay individual and his/her physician.

Frost was born in Reno, Nevada and with his family, he moved to the bay area after World War II. He is a graduate of Alameda High School, Pomona College, and the University of California Los Angeles School of Medicine. He completed his internship in New York City, his medical residency at Stanford University and his fellowship in Metabolism at the University of California San Francisco (UCSF). He served in the Public Health Service from 1969 to 1971 and again after completing his fellowship in 1974 until 1981 when the Public Health Service hospitals were closed at which time he returned to UCSF.


As a clinical investigator, he participated in the Coronary Drug Project, the first NIH sponsored clinical trial designed to determine whether lowering cholesterol helped mankind. Later he with others at UCSF participated in the first and subsequent multi-center clinical trials to determine the efficacy and safety of what was initially called mevinolin, later marketed as lovastatin (the first statin), in 1987. In addition to participating as a investigator in multiple other studies assessing lipid lowering agents, he has served in multiple trials of the efficacy and benefits of anti hypertensive treatment. He is not a professional web designer.


Selected publications are listed below:


Frost, P.H. and G.M. Reaven. Effect of Ammonium Chloride Acidosis on the Oral Glucose Tolerance and Insulin Sensitivity of Normal Rats.  Diabetes 21: 794, 1972.


Aspirin Myocardial Infarction Study Research Group.  A Randomized Controlled Trial of Aspirin in Persons Recovered From Myocardial Infarction.  JAMA 243: 661, 1980.


Frost, P.H., V.G. Shore and R.J. Havel.  Purification of Canine Post-heparin Hepatic Lipase.  Biochimica et Biophysica Acta 712: 71, 1982.


Coronary Drug Project Research Group, Ed by P. Canner. The Coronary Drug Project: Methods and Lessons of a Multicenter Clinical Trial.  Controlled Clinical Trials 4: 273, 1983..


Havel, R.J., D.B. Hunninghake, D.R. Illingworth, et al. Mevinolin in the Therapy of Familial Hypercholesterolemia.  Circulation 72: 790, 1985.


Persantine-Aspirin Reinfarction Study Research Group.  Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with Persantine and aspirin.  J. Am. Col. Cardiology 7: 251, 1986.


Canner, P.L., K.G. Berge, N.K. Wenger, J. Stamler, L. Friedman, R.J. Prineas, W. Friedewald for the Coronary Drug Project Research Group. Fifteen Year Mortality in Coronary Drug Project Patients: Long-Term Benefit with Niacin. J. Am. Col. Cardiology 6: 1245, 1987


Frost, P.H., J. Verter, and D. Miller for the Aspirin Myocardial Infarction Study Group.  Serum Lipids and Lipoproteins After Myocardial Infarction: Associations with Cardiovascular Mortality: Experience in the Aspirin Myocardial Infarction Study.  Am. Heart J. 113: 1356, 1987


Havel, R.J., D.B. Hunninghake, D.R. Illingworth, et al.  A Multicenter Study of Mevinolin (Lovastatin) in the Treatment of Heterozygous Familial Hypercholesterolemia. Ann Intern Med 107: 609, 1987


Mendel, C.M., P.H. Frost, S.T. Kunitake, and R.R. Cavalieri.  Mechanism of the Heparin-Induced Increase in the Concentration of Free Thyroxine in Plasma. J. Clin. Endocrinology and Metabolism 65: 1259, 1987


Lovastatin Study Group III.  A Multicenter Comparison of Lovastatin and Cholestyramine in the Therapy of Severe Primary Hypercholesterolemia. JAMA 260: 359, 1988


Frost PH. All Niacin is Not the Same (letter). Ann Intern Med 114:1065, 1991


SHEP Cooperative Research Group.  Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons with Isolated Systolic Hypertension: Final Results of the Systolic Hypertension in the Elderly Program (SHEP).  JAMA 265:3255-3264, 1991


Malloy MJ, Frost PH, Kane JP. Niacin-The Long and Short of It: Editorial.

West J Med 155:424-426, 1991


Lovastatin Study Groups I Through IV.  Lovastatin 5-year safety and efficacy study. Arch Intern Med 153:1079-1087, 1993


Frost PH, Davis BR, Burlando AJ, et al. Risk factors for coronary heart disease in persons with isolated systolic hypertension.  Circulation 88 (Suppl I):I-612, 1993


Frost PH, Davis BR, Burlando AJ, et al. Serum lipids and coronary heart disease in persons with isolated systolic hypertension.  Circulation 88 (Suppl I):I-612, 1993


Illingworth DR, Stein EA, Mitchel YB, Dujovne CA, Frost PH, Knopp RH, Tun P, Zupkis RV, Greguski RA.  Comparative effects of lovastatin and niacin in primary hypercholesterolemia: A prospective trial.  Arch Intern Med  154:1586-1595, 1994


Chen GC, Liu W, Duchateau P, Allaart J, Hamilton RL, Mendel CM, Lau K, Hardman DA, Frost PH, Malloy MJ, Kane JP.  Conformational differences in human apolipoprotein B-100 among subspecies of low density lipoproteins (LDL). J Biol Chem 269:29121-29128, 1994


Fielding CJ, Havel RJ, Todd KM, Yeo KE, Schloetter MC. Weinberg V, Frost PH.  Effects of dietary cholesterol and fat saturation on plasma lipoproteins in an ethnically diverse population of healthy young men. J Clin Invest  95:611-618, 1995


Pullinger CR, Hennessy LK, Chatterton JE, Liu W, Love JA, Mendel CM, Frost PH, Malloy MJ, Schumaker VN, Kane JP. Familial ligand-defective apolipoprotein B: Identification of a new mutation that decreases LDL receptor binding affinity. J Clin Invest  95:1225-1234, 1995


Stein EA, Davidson MH, Dujovne CA, Hunninghake DB, Goldberg RB, Illingworth R, Knopp RH, Miller VT, Frost P, Issacsohn JL, Mitchel YB, Melino MR, Shapiro D, Tobert JA.  Efficacy and tolerability of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: A prospective trial.  J Cardiovasc Pharmacol Therapeut 1:107-116, 1996


Frost PH, Davis BR, Burlando AJ, Curb JD, Guthrie Jr GP, Isaacson J, Wassertheil-Smoller S, Wilson AC, Stamler J, for the Systolic Hypertension in the Elderly Research Group.  Serum lipids and incidence of coronary heart disease: Findings from the Systolic Hypertension in the Elderly Program.  Circulation 94:2381-2388, 1996


Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J, for the Systolic Hypertension in the Elderly Cooperative Research Group.  Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 276-:1886-1892, 1996


Frost PH, Havel RJ.  Rationale for Use of Non-High-Density lipoprotein cholesterol rather than Low-Density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy.  Am J Cardiol 81:26B-31B, 1998


Havel RJ, Frost PH. The Role of Non-High-Density Lipoprotein-Cholesterol in Evaluation and Treatment of Lipid Disorders. Journal of Clinical Endocrinology and Metabolism 85:2105-2108, 2000


Baca A, Haber RJ, Sujishi K, Frost PH, Ng VL Artifactual undetectable HDL-cholesterol with the Beckman Synchron LX and Vitros 950 assays temporally associated with a paraprotein. Clin Chem. 2004;50: 255-6.


LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators (Frost PH - Clinical Center Director).  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-35.


Peterfy M, Ben-Zeev O, Mao HZ, Weissglas-Volkov D, Aouizerat BE, Pullinger CR, Frost PH, Kane JP, Malloy MJ, Reue K, Pajukanta P,  Doolittle MH. Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia. Nature Genetics 2007;12:1483-87.




Return to WELCOME